Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of SLx-4090 in Combination With Metformin in Subjects With Type 2 Diabetes

NCT00871936 is registered in ClinicalTrials.gov with Response Pharmaceuticals as lead sponsor.

NCT NCT00871936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00871936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of SLx-4090 in Combination With Metformin in Subjects With Type 2 Diabetes
Lead sponsor
Response Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2009
Completion date
October 31, 2009
Enrollment
82 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes